 |
|
|
| |
Phase 1/2, Multicenter, Open-label, Pharmacokinetic, Safety,
Tolerability, and Antiviral Activity Study of Dolutegravir (DTG),
a Novel Integrase Inhibitor, in Combination Regimens in
HIV-1 Infected Infants, Children, and Adolescents: P1093
|
| |
| |
Reported by jules Levin
19th Intl AIDS Conf July 22-27 2012 Wash DC
Rohan Hazra, Rolando Viani, Edward Acosta, Nan Zheng, Carmelita Alvero, Ellen O'Gara, Elizabeth Petzold, Barb Heckman, Debra Steimers, Ivy Song, Steve Piscitelli, Andrew Wiznia, on behalf of the P1093 Study Team
|
| |
|
|
|
|
|
